Vascular events caused by arteriosclerosis are the major cause of death in patients under hemodialysis (HD). Arteriosclerosis is associated with lipoprotein abnormalities such as increased serum levels of low-density lipoprotein (LDL), especially of modified LDL (M-LDL) and oxidized LDL (Ox-LDL). We examined the relationship between markers of arteriosclerosis, hemostasis, and lipid metabolism in patients with chronic renal failure, hyperlipidemia, and healthy volunteers. In patients under HD, the serum levels of total cholesterol, LDL, and triglyceride (TG) were decreased, but the serum levels of M-LDL were increased compared to HL and healthy volunteers. In patients with CRF, the serum levels of OxLDL in patients under HD were lower than in those under continuous ambulatory peritoneal dialysis or conservative therapy. The plasma levels of antithrombin and protein C were significantly lower and the plasma levels of thrombomodulin were significantly higher in patients under HD compared to those under conservative therapy. These data show that patients under HD were more in hypercoagulable state than those under conservative therapy. Among patients under HD, only the plasma levels of von Willebrand factor were significantly increased in patients with more than 30 U/L of Ox-LDL compared to those with less than 30 U/L of Ox-LDL. There was no significant difference in the tests of arteriosclerosis among M-LDL values and OxLDL values. These findings suggest that abnormalities of lipid are not the main risk factor for arteriosclerosis disease in patients under HD.
1. Japanese Society for Dialysis Therapy. An overview of regular dialysis treatment in Japan (as of December 31, 1997). J Jpn Social Dial Ther1999;32: 1-1.
2.
2. United States Renal Data System. 1999 Annual Data Report 73-88.
3.
3. Pirart J. Diabetes mellitus and its degenerative complications: A prospective study of 4,400 patients observed between 1947 and 1973. Diabetes Care1978;1:168-177, 252-261.
4.
4. Irish A. Cardiovascular disease, fibrinogen and the acutephase response: Association with lipids and blood pressure in patients with chronic renal disease. Atherosclerosis1998;137:133-133.
5.
5. Nakamura Y, Tomomura S, Tachibana K, Chida Y, Marumo F. Enhanced fibrinolytic activity during the course of hemodialysis. Clin Nephrol1992;38:90-90.
6.
6. Takagi M, Wada H, Mukai K, et al. Increased vascular endothelial cell markers in patients with chronic renal failure on maintenance haemodialysis. Blood Coagul Fibrinolysis1994;5:713-713.
7.
7. Steinberg D. Lipoprotein and atherosclerosis: A look back and a look ahead. Arteriosclerosis1983;3:283-283.
8.
8. Kannel WB, Gordon T, Castelli WP. Role of lipids and lipoprotein fractions in atherogenesis: The Framingham study. Prog Lipid Res1981;20:339-339.
9.
9. Castelli WP, Garrison RJ, Wilson PW, Abott RD, Kalousdian S, Kennel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham study. JAMA1986;256:2835-2835.
10.
10. Goldstein JL, Brown MS. The low density lipoprotein pathway and its relation to atherosclerosis. Annu Rev Biochem1977;46:897-897.
11.
11. Steinberg D, Parthasarathy S, Carew TE, Khoo JD, Witztum JL. Beyond cholesterol: Modification of low density lipoprotein that increase its atherogenicity. N Engl J Med1989;320:915-915.
12.
12. Steinbrecher UP, Parthasarathy S, Leake DS, Witztum JL, Steinberg D. Modification low density lipoprotein by endothelial cells involves lipid perioxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci USA1984;81:3883-3883.
13.
13. Heinecke JW, Rosen H, Chait A. Iron and copper promote modification of low density lipoprotein by human arterial smooth muscle cells in culture. J Clin Invest1987; 75:1890-1890.
14.
14. Steinberg D, Witztum JL. Lipoprotein and atherogenesis: Current concepts. JAMA1990;264:3047-3047.
15.
15. Ross R. The pathogenesis of atherosclerosis: An update: A perspective for the 1990's. Nature1993;362:801-801.
16.
16. Holvoet P, Collen D. Oxidized lipoproteins in atherosclerosis and thrombosis. FASEB J1994;8:1279-1279.
17.
17. Siegel JE, Weinstein MC, Russel LB, Gold MR. Recommendation for reporting cost-effectiveness analyses. For the panel cost effectiveness in health and medicine. JAMA1996;276:1339-1339.
18.
18. Vogt MT, Cauley JA, Newman AB, Kuller LH, Hulley SB. Decreased ankle/arm blood pressure index and mortality in elderly women. JAMA1993;270:465-465.
19.
19. Kannel WB, McGee DL. Update on some epidemiologic features of intermittent claudication: The Framingham Study. JAm Geriatr Soc1985;33:13-13.
20.
20. Fishbane S, Youn S, Flaster E, Adam G, Maesaka JK. Anklearm blood pressure index as a predictor of mortality in hemodialysis patients. Am J Kidney Dis1996;27: 668-668.
21.
21. Kimura K, Saika Y, Otani H, Fujii R, Mune M, Yukawa S. Factors associated with calcification of the abdominal aorta in hemodialysis patients. Kidney Int Suppl1999; 71:S238-S238.
22.
22. Deguchi K, Izumi K, Noguchi M, Wada H, Shirakawa S. Response of the cubital vein to occlusion and calcification of the abdominal aorta in patients with chronic renal failure on maintenance hemodialysis. Thromb Res1988; 49:69-69.
23.
23. Watanabe R, Wada H, Miura Y, et al. Plasma levels of total plasminogen activator inhibitor-I (PAI-I) and tPA/PAI-1 complex in patients with disseminated intravascular coagulation and thrombotic thrombocytopenic purpura. Clin Appl Thromb Hemost2001;7:229-229.
24.
24. Okugawa Y, Wada H, Noda T, et al. Increased plasma levels of tissue factor pathway inhibitor-activated factor X complex in patients with disseminated intravascular coagulation. Am J Hematol2000;65:210-210.
25.
25. Mori Y, Wada H, Okugawa Y, et al. Increased plasma thrombomodulin as a vascular endothelial cell marker in patients with thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Clin Appl Thromb Hemost2001;7:5-5.
26.
26. Ufenager J, Haux P, Katterman R. Improved method for enzymic determination of cholesterol in lipoproteins separated by electrophoresis on thin layer agarose gels. J Clin Biochem1989;27:807-807.
27.
27. Winkler K, Nauck M, Siekmeier R, Marz W, Wieland H. Determination of triglyceride in lipoproteins separated by agarose gel electrophoresis. J Lipid Res1995;36:1839-1839.
28.
28. Pelzer H, Schwarz A, Heinburger N. Determination of human thrombin-antithrombin (TAT) complex in plasma with an enzyme-linked immunosorbent assay. Thromb Hemost1987;59:101-101.
29.
29. Marlar RA, Endres-Brooks J, Miller C. Serial studies of protein C and its plasma inhibitor in patients with disseminated intravascular coagulation. Blood1985;66:59-59.
30.
30. Mimuro J, Koike Y, Sumi Y, Aoki N. Monoclonal antibodies to discrete regions in alpha 2-plasmin inhibitor. Blood1987;69:446-446.
31.
31. Westhuyzen J, Saltissi D, Healy H. Oxidation of low density lipoprotein in hemodialysis patients: Effect of dialysis and comparison with matched controls. Atherosclerosis1997;129:199-199.
32.
32. Lopes-Virella MF, Klein RL, Vilerlla G. Modification of lipoprotein in diabetes. Diabetes Metab Rev1996;12:69-69.
33.
33. Ziozuekova O, Sevanian A. Oxidative modification of lowdensity lipoprotein (LDL) in HD patients: Role in electronegative LDL formation. Blood Purif2000; 18:169-169.
34.
34. Quaschning T, Krane V, Metzger T, Wanner C. Abnormalities in uremic lipoprotein metabolism and its impact on cardiovascular disease. Am J Kidney Dis2001;38:S14-S14.
35.
35. Van Berkel TJ, Ziere GJ, Bijisterbosch MK, Kuiper J. Lipoprotein receptors and atherogenic receptor-mediated mechanism. Curr Opin Lipidol1994; 12:608-608.
36.
36. Gonen B, Goldberg AP, Harter RH, Schonfeld G. Abnormal cell-interactive properties of low density lipoproteins isolated from patients with chronic renal failure. Metabolism1985;34:10-10.
37.
37. Reinhart WH. Shear-dependence of endothelial functions. Experentia1994;50:87-87.
38.
38. Haaber AB, Eidemark I, Jensen T, Feldt-Ramussen B, Strandgaard S. Vascular endothelial cell function and cardiovascular risk factors in patients with chronic renal failure. J Am Soc Nephrol1995;5:1581-1581.
39.
39. Watanabe R, Wada H, Sakakura M, et al. Plasma levels of activated protein C-protein C inhibitor complex in patients with hypercoagulable states.Am J Hematol2000;65:35-35.
40.
40. Takagi M, Wada H, Mukai K, et al. Increased vascular endothelial cell markers in patients with chronic renal failure on maintenance haemodialysis. Blood Coagul Fibrinolysis1994;5:713-713.
41.
41. Tetta C, Gallieni M, Panichi V, Brancaccio D. Vascular calcifications as a footprint of increased calcium load and chronic inflammation in uremic patients: A need for a neutral calcium balance during hemodialysis?Int J Artif Organs2002;25:18-18.
